The retrospective study recently published by Margolis et al. ([@B1]) raises many questions. First, it appears that the excluded cohort had a lower extremity amputation (LEA) rate of 4.5% in the first 28 days. This seems high. Previous studies have shown overall amputation rates (major and minor) after 1 year of 12.5--22.6% in two smaller cohort studies of sicker patients ([@B2],[@B3]). Given that the excluded cohort was defined as having "adequate lower extremity arterial flow" (diagnostic method unknown), these results suggest that the excluded cohort was either at inherently higher risk for an LEA or that basic wound care was poorly conducted.

Second, since the detailed selection criteria for hyperbaric oxygen therapy (HBOT) at the former National Healing Corporation were not reported, it remains unclear if they were medically appropriate. HBOT is indicated for diabetic foot ulcers (DFUs) that have failed to respond to adequate basic wound care after 4 weeks (including appropriate debridement, vascular screening for significant peripheral arterial disease, and/or local wound hypoxia, adequate offloading, and infection management). Additionally, current best practice is to assess DFUs with transcutaneous oximetry while breathing sea level air to confirm that wounds are hypoxic and thus unlikely to heal spontaneously and confirming possible benefit from HBOT with in-chamber oximetry ([@B4]). The provision of HBOT to Wagner grade 2 lesions is puzzling because prospective HBOT trials have focused on Wagner grade 3 and above, mirroring Medicare coverage policy. Since none of the advanced therapeutics currently used in wound care have been tested in DFUs above Wagner grade 2, HBOT stands alone with RCT evidence of efficacy in Wagner 3/4 grade ulcers.

Third, the method of analysis in this study has shortcomings. Although propensity scoring as a means of adjusting for the severity of wounds and patient comorbidities may be a viable approach, if conducted inappropriately it can lead to increased rather than decreased bias ([@B5]). Many other confounders can affect outcomes directly, such as renal failure, smoking, chronic heart failure, level of tissue exposed, offloading, debridement, infection severity, management of infection, ambulation, and immunosuppression (e.g., long-term steroid use/concurrent chemotherapy). Sensitivity analysis for the assumed distribution of an individual potential confounder, as reported in this article, is inadequate to account for the potential effects of such a long list of known confounders---and can make no allowance for any further confounding factors of which we are unaware.

In summary, we believe the results from this retrospective cohort study are not necessarily generalizable to other wound-care populations. We agree with Margolis et al. ([@B1]) that "it is entirely likely that HBO therapy enhances a specific aspect of wound repair and should not be used as a single agent to completely heal a wound." However, we are not confident that the retrospective analysis by Margolis et al. of practice in a single wound-care organization sheds light on the difference between efficacy and effectiveness of HBOT in DFU patients as implemented in well-designed clinical practice guidelines. Most importantly, this study should energize all organizations to rereview how HBOT is used for DFUs.
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